AR and prostate cancer: Similarly, in organoid models of prostate cancer and laryngeal squamous cell carcinoma, activating the androgen receptor (AR)/GPX4 axis and inhibiting endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) have both led to improved therapeutic outcomes [75,76].